Art. -Nr.: HY-N0656A

(+)-Usnic acid

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer and anti-inflammatory activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.64%
CAS. Nr.: 7562-61-0
Formel: C₁₈H₁₆O₇
Molecular Weight:344.32

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

(+)-Usnic acid Chemical Structure

CAS. Nr.: 7562-61-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

mTORC1

mTORC2

Alle mTOR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
3LL cell line	IC₅₀	35.1 μM Compound: (-)-UA, usnic acid	Cytotoxicity against mouse 3LL CRL 1642 cells after 48 hrs by MTT assay Cytotoxicity against mouse 3LL CRL 1642 cells after 48 hrs by MTT assay	[PMID: 18558490]
BT-474	IC₅₀	15.1 μM Compound: 1	Antiproliferative activity against human BT-474 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-474 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
DU-145	IC₅₀	45.9 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay	[PMID: 18558490]
K562	IC₅₀	21.8 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay	[PMID: 18558490]
L1210	IC₅₀	17.4 μM Compound: (-)-UA, usnic acid	Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay	[PMID: 18558490]
MCF7	IC₅₀	11.2 μM Compound: 1	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
MCF7	IC₅₀	51.7 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay	[PMID: 18558490]
MDA-MB-231	IC₅₀	13.1 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
MDA-MB-231	IC₅₀	13.7 μM Compound: 1	Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell migration after 23 hrs by by scratch wound healing assay Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell migration after 23 hrs by by scratch wound healing assay	[PMID: 28245124]
MDA-MB-231	IC₅₀	14.2 μM Compound: 1	Anti-invasive activity in human MDA-MB-231 cells after 24 hrs by microscopic analysis Anti-invasive activity in human MDA-MB-231 cells after 24 hrs by microscopic analysis	[PMID: 28245124]
MDA-MB-468	IC₅₀	13.7 μM Compound: 1	Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
MDCK	ED₅₀	13.1 μM Compound: (-)-1	Antiviral activity against rimantidine, amantidine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication after 1 hrs by hemagglutination assay Antiviral activity against rimantidine, amantidine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication after 1 hrs by hemagglutination assay	[PMID: 25464881]
MDCK	ED₅₀	14.5 μM Compound: (-)-1	Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method	[PMID: 23099095]
SK-BR-3	IC₅₀	14.4 μM Compound: 1	Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
T47D	IC₅₀	15.9 μM Compound: 1	Antiproliferative activity against human T47D cells incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
U-251	IC₅₀	19.7 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay	[PMID: 18558490]

In Vitro

(+)-Usnic acid (10_-6.5-10_-3.5 M, 72 h) exhibits antiproliferative activity against breast cancer cell lines^[1].
(+)-Usnic acid ( 15 μM, 72 h) induces autophagy and inhibits cell migration and invasion in human breast cancer cell lines^[1].
(+)-Usnic acid (0.2% (wt/vol), 3 days) inhibits biofilm formation by S. aureus. with a MICs value of 32 μg/mL^[2].

mean IC₅₀±SEM of (+)-Usnic acid against each breast cancer cell line^[1]

Breast cancer cell line	MDA-MB-231	MDA-MB-468	MCF-7	T-47D	BT-474	SK-BR-3
IC₅₀ (μM)	13.1	13.7	11.2	15.9	15.1	14.4

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Breast cancer cell lines
Concentration:

10_-6.5-10_-3.5 M
Incubation Time:

72 h
Result:

Exhibited a moderate, albeit pan antiproliferative activity against breast cancer cell lines at low micromolar concentrations.

Cell Autophagy Assay^[1]

Cell Line:

Breast cancer cell lines
Concentration:

15 μM
Incubation Time:

72 h
Result:

Induced distinct autophagic vacuoles and upregulated the autophagic marker LC3 and Beclin-1.

Chemical Information

CAS. Nr. 7562-61-0
Appearance Solid
Molecular Weight 344.32
Formel C₁₈H₁₆O₇
Color Light yellow to yellow
SMILES

O=C([C@@]1(C)C(OC2=C(C(C)=O)C(O)=C(C)C(O)=C12)=C3)C(C(C)=O)C3=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

ACS Infect Dis

Restoring Colistin Sensitivity and Combating Biofilm Formation: Synergistic Effects of Colistin and Usnic Acid against Colistin-Resistant Enterobacteriaceae. [Abstract]

2023 Dec 8;9(12):2457-2470. PMID: 37944020
Allergy Asthma Clin Immunol

KIF2A decreases IL-33 production and attenuates allergic asthmatic inflammation. [Abstract]

2022 Jun 19;18(1):55. PMID: 35718777

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 1.92 mg/mL (5.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9043 mL

14.5214 mL

29.0428 mL

5 mM

0.5809 mL

2.9043 mL

5.8085 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.63 mg/mL (1.83 mM); Clear solution

This protocol yields a clear solution of ≥ 0.63 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ebrahim HY, et al. Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies. J Nat Prod. 2017 Apr 28;80(4):932-952. [Content Brief]

[2]. Francolini I, et al. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob Agents Chemother. 2004;48(11):4360-4365. [Content Brief]

[3]. Vijayakumar CS, et al. Anti-inflammatory activity of (+)-usnic acid. Fitoterapia. 2000 Sep;71(5):564-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9043 mL	14.5214 mL	29.0428 mL	72.6069 mL
DMSO	5 mM	0.5809 mL	2.9043 mL	5.8086 mL	14.5214 mL

Keywords

(+)-Usnic acid

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

(+)-Usnic acid

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) (+)-Usnic acid

Alle mTOR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(+)-Usnic acid Related Classifications

HY-N0656A Related Classifications